# Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

> **NCT00345683** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 4021 (actual)

## Conditions studied

- Haemophilus Influenzae Type b
- Neisseria Meningitidis

## Interventions

- **BIOLOGICAL:** GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)
- **BIOLOGICAL:** PedvaxHIB
- **BIOLOGICAL:** Prevnar
- **BIOLOGICAL:** M-M-R II
- **BIOLOGICAL:** Varivax

## Key facts

- **NCT ID:** NCT00345683
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-09
- **Final completion:** 2008-11
- **Target enrollment:** 4021 (ACTUAL)
- **Last updated:** 2016-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345683, "Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00345683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*